<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Vasoactive intestinal polypeptide</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Vasoactive intestinal polypeptide</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Vasoactive intestinal polypeptide</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Rodger A Liddle, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">J Thomas Lamont, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Shilpa Grover, MD, MPH, AGAF</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jul 11, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Vasoactive intestinal polypeptide (VIP) is a neuropeptide that functions as a neuromodulator and neurotransmitter. It is a potent vasodilator, regulates smooth muscle activity, epithelial cell secretion, and blood flow in the gastrointestinal tract [<a href="#rid1">1-3</a>]. As a chemical messenger, it functions as a neurohormone and paracrine mediator, being released from nerve terminals and acting locally on receptor-bearing cells.</p><p>The VIP receptor is a member of a unique class of G protein-coupled receptors. These receptors share a significant degree of sequence homology (&gt;50 percent), which distinguishes them from members of the rhodopsin/beta-adrenergic family (class I) [<a href="#rid4">4</a>]. (See  <a class="medical medical_review" href="/z/d/html/3804.html" rel="external">"Peptide hormone signal transduction and regulation"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">MOLECULAR FORMS</span><span class="headingEndMark"> — </span>Like other gastrointestinal peptides, vasoactive intestinal polypeptide (VIP) is synthesized as a precursor molecule of 170 amino acids containing a signal peptide of 22 amino acids, which is then cleaved to the active peptide of 28 amino acids [<a href="#rid5">5,6</a>]. The gene encoding this peptide resides on chromosome 6 [<a href="#rid7">7</a>]. Some studies have demonstrated local control of VIP gene expression as VIP mRNA does not always parallel the peptide product [<a href="#rid8">8</a>]. These data suggest regulation at the post-transcriptional stage may be essential for normal VIP secretion [<a href="#rid8">8</a>].</p><p>The VIP peptide is remarkably well conserved across species and is identical in human, cow, pig, rat, dog, and goat species [<a href="#rid3">3</a>]. Even across species, amino acid substitutions are conservative and usually do not result in changes in bioactivity. VIP shares 68 percent sequence homology with pituitary adenylyl cyclase-activating peptide (PACAP).</p><p>Alternative peptides derived from the VIP gene include peptide histidine isoleucine (PHI) [<a href="#rid9">9</a>], peptide histidine methionine [<a href="#rid10">10,11</a>], and peptide histidine valine [<a href="#rid6">6</a>]. Although the functional significance of these peptides is unclear, PHI is known to stimulate intestinal fluid secretion [<a href="#rid12">12</a>].</p><p class="headingAnchor" id="H3"><span class="h1">TISSUE DISTRIBUTION</span><span class="headingEndMark"> — </span>Vasoactive intestinal polypeptide (VIP) is expressed in the peripheral/enteric and central nervous systems. It is primarily localized to neurons, although it is also produced by other cell types. More recent studies have demonstrated that VIP is produced by immunomodulatory T cells. Immunolocalization studies have demonstrated VIP in nerve fibers located in many organs, including the luminal gastrointestinal tract [<a href="#rid13">13,14</a>], respiratory airways [<a href="#rid6">6</a>], pancreas [<a href="#rid15">15</a>], sensory organs [<a href="#rid16">16</a>], and reproductive system [<a href="#rid17">17</a>]. Cloning of the VIP receptor has provided complementary information on the localization of the VIP receptor [<a href="#rid16">16,18,19</a>].</p><p class="headingAnchor" id="H4"><span class="h1">RECEPTORS</span><span class="headingEndMark"> — </span>G protein-coupled receptors (GPCRs) have been grouped into subfamilies based upon their amino acid sequence. The <a class="drug drug_general" data-topicid="10259" href="/z/d/drug information/10259.html" rel="external">secretin</a>/vasoactive intestinal polypeptide (VIP) family of receptors (consisting of receptors for VIP, secretin, glucagon, calcitonin, parathyroid hormone, pituitary adenylyl cyclase-activating peptide [PACAP], and others) is structurally unique. Given the considerable overlap between VIP and PACAP receptor agonist binding, nomenclature for these receptors has been standardized [<a href="#rid20">20</a>].</p><p>There are two known VIP receptor types (vasoactive intestinal polypeptide receptor 1 [VPAC<sub>1</sub>] and vasoactive intestinal polypeptide receptor 2 [VPAC<sub>2</sub>]). Notably, the PACAP receptor (PAC1) also binds VIP, although with much lower affinity.</p><p>Class II GPCRs lack structural signature sequences present in the rhodopsin/ß-adrenergic receptor family (such as a DRY motif - Asp-Arg-Tyr - at the end of the third transmembrane spanning domain), which appear to be important in receptor coupling to G proteins. VIP binds to its specific heptahelical membrane receptor and activates the heterotrimeric G protein, Gs, leading to elevation of cellular cAMP levels. This second messenger begins the signaling cascade that initiates appropriate cell physiologic responses. (See  <a class="medical medical_review" href="/z/d/html/3804.html" rel="external">"Peptide hormone signal transduction and regulation"</a>.)</p><p>The mechanisms for VIP receptor signal termination include receptor phosphorylation mediated by G protein-coupled receptor kinases. Interestingly, the mechanism for VIP receptor internalization is distinct from that used by prototypical Class I GPCRs. This observation suggests that novel proteins may be involved in its regulation.</p><p>VIP receptors and mRNA are found in various tissues in the gastrointestinal tract and brain. Receptors are abundant on smooth muscle of sphincters of the lower esophagus, ampulla of Vater, and rectum. In these locations, VIP regulates sphincter relaxation. VIP receptors on pancreatic acinar and duct cells and enteric mucosal cells mediate fluid secretion in these organs.</p><p class="headingAnchor" id="H5"><span class="h1">VIP RELEASE</span><span class="headingEndMark"> — </span>As mentioned above, vasoactive intestinal polypeptide (VIP) was originally identified in the gastrointestinal tract and named for its potent vasodilatation [<a href="#rid2">2</a>]. It was subsequently recognized as a neurotransmitter in the central and peripheral nervous systems [<a href="#rid21">21,22</a>]. Because VIP is released from neurons, it is likely that the majority of measurable VIP in serum is of neuronal origin [<a href="#rid23">23</a>]. Serum VIP levels are low and do not appreciably change with a meal. In pathologic conditions, like pancreatic cholera (watery diarrhea-hypokalemia-achlorhydria, WDHA, or Verner-Morrison syndrome [<a href="#rid24">24</a>]), VIP levels can be extraordinarily high [<a href="#rid25">25,26</a>]. Although VIP-secreting tumors are rare, in adults, most VIPomas are found in the pancreas, however, in children the majority of VIP-secreting tumors are ganglioneuromas or ganglioneuroblastomas. (See  <a class="medical medical_review" href="/z/d/html/2610.html" rel="external">"VIPoma: Clinical manifestations, diagnosis, and management"</a>.)</p><p>Because VIP is derived from a precursor peptide (see <a class="local">'Molecular forms'</a> above) it is released along with other peptides, including primarily peptide histidine isoleucine and/or peptide histidine methionine [<a href="#rid27">27-29</a>]. It is also released with enzymes of the nitric oxide (NO) synthesis cascade, specifically NO synthase in neurons of the myenteric plexus [<a href="#rid30">30,31</a>]. The physiologic mechanisms of this co-release are an active area of investigation [<a href="#rid32">32</a>].</p><p class="headingAnchor" id="H6"><span class="h1">VIP PHYSIOLOGY</span><span class="headingEndMark"> — </span>Vasoactive intestinal polypeptide (VIP) is an important neurotransmitter throughout the central and peripheral nervous systems. Due to its wide distribution, VIP has effects on many organ systems (<a class="graphic graphic_table graphicRef59411" href="/z/d/graphic/59411.html" rel="external">table 1</a>) [<a href="#rid21">21</a>]. In particular, it:</p><p class="bulletIndent1"><span class="glyph">●</span>Stimulates gastrointestinal epithelial secretion [<a href="#rid25">25,26</a>] and absorption [<a href="#rid33">33</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>Promotes fluid and bicarbonate secretion from bile duct cholangiocytes [<a href="#rid34">34</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>Is a potent relaxer of smooth muscle, including the lower esophageal sphincter [<a href="#rid35">35</a>] and colon [<a href="#rid36">36</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>Increases the growth of certain adenocarcinomas [<a href="#rid37">37</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>Causes vasodilation.</p><p class="bulletIndent1"><span class="glyph">●</span>Exerts anti-inflammatory actions.</p><p></p><p>VIP, along with nitric oxide, is a primary component of the non-adrenergic non-cholinergic nerve transmission in the gut [<a href="#rid38">38,39</a>]. Gastrointestinal smooth muscle exhibits a basal tone, or sustained tension, which is generated by rhythmic depolarizations (also called slow waves) of the smooth muscle membrane. Contractions occur when the slow waves reach a threshold level for calcium entry through calcium channels [<a href="#rid39">39</a>]. VIP serves as an inhibitory transmitter of this rhythmic activity, causing membrane hyperpolarization and subsequent relaxation of gastrointestinal smooth muscle [<a href="#rid39">39,40</a>]. In the intestine, VIP neurons project not only to other enteric neurons but also to muscle and epithelial cells, where they regulate circular muscle and epithelial chloride secretion.</p><p>VIP is an important neuromodulator in sphincters of the gastrointestinal tract including the lower esophageal sphincter and sphincter of Oddi. In certain pathological conditions, such as achalasia and Hirschsprung disease, the lack of VIP innervation is believed to have a major role in defective esophageal relaxation and bowel dysmotility.</p><p>VIP has immunomodulatory properties [<a href="#rid41">41,42</a>]. It is produced by a population of Th2 lymphocytes and promotes Th2-type immune responses [<a href="#rid43">43</a>]. In antigen-primed CD4 T cells in vitro, VIP inhibits Th1 cytokines interferon gamma and IL-2. In macrophages and dendritic cells, VIP induces Th2 cytokines IL-4 and IL-5. In vivo, VIP administration increases the ratio of Th2/Th1 cells. VIP also downregulates TNF-alpha expression. Thus, VIP appears to regulate the balance between pro-inflammatory and anti-inflammatory influences by inducing the emergence of T-cell effectors [<a href="#rid44">44</a>]. As a result, VIP has endogenous anti-inflammatory activity. Beneficial effects of VIP have been demonstrated in animal models of arthritis, sepsis, and pancreatitis [<a href="#rid45">45</a>]. Considerable evidence suggests that VIP may participate in the pathogenesis of inflammatory bowel disease [<a href="#rid46">46,47</a>]. These effects are likely due to its anti-inflammatory effects, but VIP also appears to regulate intestinal epithelial barrier function through effects on tight junction proteins [<a href="#rid48">48</a>]. Although reports suggested that VIP could reduce the histopathological severity in an experimental model of colitis, these results have not been uniformly reproduced [<a href="#rid49">49</a>].</p><p>VIP has effects on pulmonary vasculature and may play a role in pulmonary arterial hypertension. VIP has been shown to relax pulmonary vascular smooth muscle and attenuate vasoconstriction induced by endothelin and other mediators [<a href="#rid50">50</a>]. These actions likely contribute to the observation that mice with targeted disruption of the VIP gene have a phenotype that is remarkably similar to spontaneous pulmonary arterial hypertension with vascular remodeling and lung inflammation [<a href="#rid51">51</a>]. The antiproliferative effects of VIP may limit pulmonary vascular remodeling, and VIP is being investigated as a possible treatment for pulmonary arterial hypertension [<a href="#rid52">52</a>].</p><p>Mice with targeted disruption of the VIP gene have a phenotype that is remarkably similar to spontaneous pulmonary arterial hypertension with vascular remodeling and lung inflammation [<a href="#rid51">51</a>]. Interestingly, these mice also have disturbances in circadian rhythm [<a href="#rid53">53</a>] as well as altered inflammatory responses [<a href="#rid54">54</a>].</p><p>VIP has potent vasodilatory effects on the vasculature of the head and neck, and elevated VIP levels have been found in the blood of patients with migraine headaches [<a href="#rid55">55,56</a>]. However, despite its direct vascular effects, VIP does not appear to induce migraine attacks [<a href="#rid57">57</a>].</p><p>VIP increases secretion of bombesin-like peptides, which are autocrine growth factors for small cell lung cancer. Therefore, it is possible that VIP could indirectly contribute to lung cancer growth [<a href="#rid58">58</a>].</p><p>VIP receptors 1 and 2 (VPAC<sub>1</sub> and VPAC<sub>2</sub>) are expressed on a number of common cancers including lung, breast, and prostate. Understandably, VIP has prominent growth promoting effects on such cancers [<a href="#rid59">59</a>].</p><p>Pancreatic islet beta cells express VPAC<sub>1</sub>, VPAC<sub>2</sub>, and the pituitary adenylyl cyclase-activating peptide (PACAP) receptor (PAC1) and VIP knockout mice exhibit elevated plasma glucose levels, indicating that VIP may influence beta cell function [<a href="#rid60">60</a>].</p><p class="headingAnchor" id="H7"><span class="h1">CLINICAL IMPLICATIONS</span><span class="headingEndMark"> — </span>One of the most common clinical uses of vasoactive intestinal polypeptide (VIP) is in the radioimmunoassay for serum VIP quantitation in the evaluation of chronic secretory or high-volume diarrhea [<a href="#rid61">61</a>]. Patients with a VIP-producing tumor usually present with voluminous diarrhea (ie, pancreatic cholera) [<a href="#rid26">26,62</a>]. In contrast, patients with small volume, infrequent diarrhea are unlikely to have a VIP-producing tumor. (See  <a class="medical medical_review" href="/z/d/html/2610.html" rel="external">"VIPoma: Clinical manifestations, diagnosis, and management"</a>.)</p><p>VIP-secreting tumors, various pancreatic adenocarcinomas, and carcinoid tumors express VIP receptors. Thus, radionuclide imaging using radiolabeled VIP analogues has been used to locate and guide resection of these often difficult to find tumors [<a href="#rid63">63-65</a>]. Improved understanding about the receptors expressed by various tumors should permit improved localization for surgical resection and chemotherapy.</p><p>Vasoactive intestinal polypeptide receptor 1 (VPAC<sub>1</sub>) has been found in prostate cancer [<a href="#rid66">66</a>], and it has been proposed that VPAC<sub>1</sub> cells shed into the urine could be used in prostate cancer diagnosis [<a href="#rid67">67</a>]. Some breast, lung, gastric, pancreas, colon, bladder, and central nervous system tumors express VPAC<sub>1</sub>, VPAC<sub>2</sub>, or the PACAP (PAC1) receptors and may contribute to cancer growth and differentiation [<a href="#rid68">68</a>].</p><p>Mast cell infiltration and VIP release has been associated with irritable bowel syndrome with diarrhea (IBS-D) [<a href="#rid69">69</a>]. Moreover, plasma VIP levels have been reported to be elevated in patients with irritable bowel syndrome (IBS) [<a href="#rid70">70</a>]. Interestingly, a population of mast cells express VPAC<sub>1</sub> rendering them susceptible to VIP stimulation. It has been proposed that altered mast cell function may contribute to colonic mucosal barrier dysfunction in IBS [<a href="#rid71">71</a>]. Despite initial enthusiasm, it remains to be determined if circulating VIP levels can be used as a maker of IBS. This is particularly problematic since elevated VIP levels have also been reported in inflammatory bowel diseases including Crohn disease and ulcerative colitis [<a href="#rid72">72</a>]. Therefore, it seems unlikely that VIP measurements will have sufficient specificity to be clinically useful.</p><p>A deficiency of VIP-secreting neurons has been implicated in a number of disease states. As an example, patients with Hirschsprung's disease have a deficiency of VIP-containing ganglion cells in the colon [<a href="#rid73">73</a>]. Similarly, patients with achalasia have reduced VIP levels in smooth muscle of the distal esophagus [<a href="#rid74">74</a>]. Interestingly, sweat glands from patients with cystic fibrosis have reduced VIP-innervation [<a href="#rid75">75</a>].</p><p>Therapeutic uses of VIP or VIP analogues are being established. VIP has been used to treat pulmonary hypertension and sarcoidosis [<a href="#rid76">76</a>]. VIP has the advantage of targeting both the innate and adaptive immune systems and affecting a large number of proinflammatory chemokines and cytokines. A role has been suggested for treating acute and chronic inflammatory and autoimmune diseases, including septic shock, rheumatoid arthritis, multiple sclerosis, Crohn disease, diabetes and neurodegenerative diseases such as Parkinson’s disease [<a href="#rid77">77</a>]. A major limitation has been route of delivery because, as a peptide, VIP requires parenteral or nasal administration. It is also susceptible to rapid proteolytic degradation; therefore, strategies are being developed to extend its short half-life yet avoid undesirable side effects such as hypotension.</p><p class="headingAnchor" id="H460959919"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span>Vasoactive intestinal polypeptide (VIP) is a neuropeptide that functions as a neuromodulator and neurotransmitter. It is a potent vasodilator, regulates smooth muscle activity, epithelial cell secretion, and blood flow in the gastrointestinal tract. As a chemical messenger, it functions as a neurohormone and paracrine mediator. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>VIP is synthesized as a precursor molecule, which is then cleaved to the active peptide. (See <a class="local">'Molecular forms'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>VIP is expressed in the peripheral/enteric and central nervous systems. It is primarily localized to neurons, although it is also produced by other cell types including immunomodulatory T cells. (See <a class="local">'Tissue distribution'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>There are two known VIP receptor types (VIP type 1 and VIP type 2 receptors). VIP receptors and mRNA are found in various tissues in the gastrointestinal tract and brain. Receptors are abundant on smooth muscle of sphincters of the lower esophagus, ampulla of Vater, and rectum. In these locations, VIP regulates sphincter relaxation. VIP receptors on pancreatic acinar and duct cells and enteric mucosal cells mediate fluid secretion in these organs. (See <a class="local">'Receptors'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>VIP has effects on many organ systems. It stimulates gastrointestinal epithelial secretion and absorption, promotes fluid and bicarbonate secretion from bile duct cholangiocytes, relaxes smooth muscles, including the lower esophageal sphincter and colon, increases the growth of certain adenocarcinomas, causes vasodilation, and exerts anti-inflammatory actions. (See <a class="local">'VIP physiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with a VIP-producing tumor usually present with voluminous diarrhea (ie, pancreatic cholera). Clinical uses of VIP include radioimmunoassay for serum VIP quantitation in the evaluation of chronic secretory or high volume diarrhea.</p><p></p><p class="bulletIndent1">Radionuclide imaging has been used to locate and guide resection of VIP-secreting tumors, pancreatic adenocarcinomas, and carcinoid tumors that express VIP receptors. (See <a class="local">'Clinical implications'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Future therapeutic uses of VIP or VIP analogues may include treating acute and chronic inflammatory and autoimmune diseases, including septic shock, rheumatoid arthritis, multiple sclerosis, Parkinson disease, Crohn disease, and diabetes. (See <a class="local">'Clinical implications'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Said SI, Mutt V. Polypeptide with broad biological activity: isolation from small intestine. Science 1970; 169:1217.</a></li><li><a class="nounderline abstract_t">Said SI, Mutt V. Potent peripheral and splanchnic vasodilator peptide from normal gut. Nature 1970; 225:863.</a></li><li class="breakAll">Dockray GJ. Vasoactive intestinal polypeptide and related peptides. In: Gut Hormones: Biochemistry and Physiology, 1st ed, Walsh JH, Dockray GJ (Eds), Raven Press, New York 1994. p.447.</li><li><a class="nounderline abstract_t">Birnbaumer M. Mutations and diseases of G protein coupled receptors. J Recept Signal Transduct Res 1995; 15:131.</a></li><li><a class="nounderline abstract_t">Linder S, Barkhem T, Norberg A, et al. Structure and expression of the gene encoding the vasoactive intestinal peptide precursor. Proc Natl Acad Sci U S A 1987; 84:605.</a></li><li><a class="nounderline abstract_t">Maggi CA, Giachetti A, Dey RD, Said SI. Neuropeptides as regulators of airway function: vasoactive intestinal peptide and the tachykinins. Physiol Rev 1995; 75:277.</a></li><li><a class="nounderline abstract_t">Gozes I, Nakai H, Byers M, et al. Sequential expression in the nervous system of c-myb and VIP genes, located in human chromosomal region 6q24. Somat Cell Mol Genet 1987; 13:305.</a></li><li><a class="nounderline abstract_t">Gozes I, Shani Y, Rostène WH. Developmental expression of the VIP-gene in brain and intestine. Brain Res 1987; 388:137.</a></li><li><a class="nounderline abstract_t">Christofides ND, Yiangou Y, Blank MA, et al. Are peptide histidine isoleucine and vasoactive intestinal peptide co-synthesised in the same pro-hormone? Lancet 1982; 2:1398.</a></li><li><a class="nounderline abstract_t">Bodner M, Fridkin M, Gozes I. Coding sequences for vasoactive intestinal peptide and PHM-27 peptide are located on two adjacent exons in the human genome. Proc Natl Acad Sci U S A 1985; 82:3548.</a></li><li><a class="nounderline abstract_t">Yiangou Y, Williams SJ, Bishop AE, et al. Peptide histidine-methionine immunoreactivity in plasma and tissue from patients with vasoactive intestinal peptide-secreting tumors and watery diarrhea syndrome. J Clin Endocrinol Metab 1987; 64:131.</a></li><li><a class="nounderline abstract_t">Ghiglione M, Christofides ND, Yiangou Y, et al. PHI stimulates intestinal fluid secretion. Neuropeptides 1982; 3:79.</a></li><li><a class="nounderline abstract_t">Ekblad E, Winther C, Ekman R, et al. Projections of peptide-containing neurons in rat small intestine. Neuroscience 1987; 20:169.</a></li><li><a class="nounderline abstract_t">Porter AJ, Wattchow DA, Brookes SJ, Costa M. Projections of nitric oxide synthase and vasoactive intestinal polypeptide-reactive submucosal neurons in the human colon. J Gastroenterol Hepatol 1999; 14:1180.</a></li><li><a class="nounderline abstract_t">Adeghate E. Distribution of calcitonin-gene-related peptide, neuropeptide-Y, vasoactive intestinal polypeptide, cholecystokinin-8, substance P and islet peptides in the pancreas of normal and diabetic rats. Neuropeptides 1999; 33:227.</a></li><li><a class="nounderline abstract_t">Kitanishi T, Suzuki M, Kitano H, et al. Immunohistochemical detection of vasoactive intestinal polypeptide (VIP) and the VIP receptor in the rat inner ear. Acta Otolaryngol Suppl 1998; 539:52.</a></li><li><a class="nounderline abstract_t">Houdeau E, Prudhomme MJ, Rousseau JP. Regional difference in the distribution of vasoactive intestinal polypeptide-immunoreactive nerve fibres along the uterus and between myometrial muscle layers in the rat. Histochem J 1998; 30:525.</a></li><li><a class="nounderline abstract_t">Alexandre D, Anouar Y, Jegou S, et al. A cloned frog vasoactive intestinal polypeptide/pituitary adenylate cyclase-activating polypeptide receptor exhibits pharmacological and tissue distribution characteristics of both VPAC1 and VPAC2 receptors in mammals. Endocrinology 1999; 140:1285.</a></li><li><a class="nounderline abstract_t">Vertongen P, Schiffmann SN, Gourlet P, Robberecht P. Autoradiographic visualization of the receptor subclasses for vasoactive intestinal polypeptide (VIP) in rat brain. Ann N Y Acad Sci 1998; 865:412.</a></li><li><a class="nounderline abstract_t">Harmar AJ, Arimura A, Gozes I, et al. International Union of Pharmacology. XVIII. Nomenclature of receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide. Pharmacol Rev 1998; 50:265.</a></li><li><a class="nounderline abstract_t">Fahrenkrug J. Transmitter role of vasoactive intestinal peptide. Pharmacol Toxicol 1993; 72:354.</a></li><li><a class="nounderline abstract_t">Pellesi L, Al-Karagholi MA, De Icco R, et al. Effect of Vasoactive Intestinal Polypeptide on Development of Migraine Headaches: A Randomized Clinical Trial. JAMA Netw Open 2021; 4:e2118543.</a></li><li><a class="nounderline abstract_t">Bitar KN, Said SI, Weir GC, et al. Neural release of vasoactive intestinal peptide from the gut. Gastroenterology 1980; 79:1288.</a></li><li><a class="nounderline abstract_t">Verner JV, Morrison AB. Endocrine pancreatic islet disease with diarrhea. Report of a case due to diffuse hyperplasia of nonbeta islet tissue with a review of 54 additional cases. Arch Intern Med 1974; 133:492.</a></li><li><a class="nounderline abstract_t">Bloom SR. Vasoactive intestinal peptide, the major mediator of the WDHA (pancreatic cholera) syndrome: value of measurement in diagnosis and treatment. Am J Dig Dis 1978; 23:373.</a></li><li><a class="nounderline abstract_t">Masel SL, Brennan BA, Turner JH, et al. Pancreatic vasoactive intestinal polypeptide-oma as a cause of secretory diarrhoea. J Gastroenterol Hepatol 2000; 15:457.</a></li><li><a class="nounderline abstract_t">Lundberg JM, Fahrenkrug J, Larsson O, Anggård A. Corelease of vasoactive intestinal polypeptide and peptide histidine isoleucine in relation to atropine-resistant vasodilation in cat submandibular salivary gland. Neurosci Lett 1984; 52:37.</a></li><li><a class="nounderline abstract_t">Holst JJ, Fahrenkrug J, Knuhtsen S, et al. VIP and PHI in the pig pancreas: coexistence, corelease, and cooperative effects. Am J Physiol 1987; 252:G182.</a></li><li><a class="nounderline abstract_t">Yasui A, Naruse S, Yanaihara C, et al. Corelease of PHI and VIP by vagal stimulation in the dog. Am J Physiol 1987; 253:G13.</a></li><li><a class="nounderline abstract_t">Li CG, Rand MJ. Nitric oxide and vasoactive intestinal polypeptide mediate non-adrenergic, non-cholinergic inhibitory transmission to smooth muscle of the rat gastric fundus. Eur J Pharmacol 1990; 191:303.</a></li><li><a class="nounderline abstract_t">Van Geldre LA, Lefebvre RA. Interaction of NO and VIP in gastrointestinal smooth muscle relaxation. Curr Pharm Des 2004; 10:2483.</a></li><li><a class="nounderline abstract_t">Fahrenkrug J, Hannibal J. Neurotransmitters co-existing with VIP or PACAP. Peptides 2004; 25:393.</a></li><li><a class="nounderline abstract_t">Barada KA, Saadé NE, Atweh SF, Nassar CF. Neural mediation of vasoactive intestinal polypeptide inhibitory effect on jejunal alanine absorption. Am J Physiol 1998; 275:G822.</a></li><li><a class="nounderline abstract_t">Cho WK, Boyer JL. Vasoactive intestinal polypeptide is a potent regulator of bile secretion from rat cholangiocytes. Gastroenterology 1999; 117:420.</a></li><li><a class="nounderline abstract_t">Rattan S, Fan YP, Chakder S. Mechanism of inhibition of VIP-induced LES relaxation by heme oxygenase inhibitor zinc protoporphyrin IX. Am J Physiol 1999; 276:G138.</a></li><li><a class="nounderline abstract_t">Motomura Y, Chijiiwa Y, Yasuda O, et al. Thyrotropin-releasing hormone interacts with vasoactive intestinal peptide-specific receptor in guinea pig cecal circular smooth muscle cells. Regul Pept 2000; 87:41.</a></li><li><a class="nounderline abstract_t">Jiang S, Kopras E, McMichael M, et al. Vasoactive intestinal peptide (VIP) stimulates in vitro growth of VIP-1 receptor-bearing human pancreatic adenocarcinoma-derived cells. Cancer Res 1997; 57:1475.</a></li><li><a class="nounderline abstract_t">Goyal RK, Rattan S, Said SI. VIP as a possible neurotransmitter of non-cholinergic non-adrenergic inhibitory neurones. Nature 1980; 288:378.</a></li><li><a class="nounderline abstract_t">Grider JR. Interplay of VIP and nitric oxide in regulation of the descending relaxation phase of peristalsis. Am J Physiol 1993; 264:G334.</a></li><li><a class="nounderline abstract_t">Sababi M, Hällgren A, Nylander O. Interaction between prostanoids, NO, and VIP in modulation of duodenal alkaline secretion and motility. Am J Physiol 1996; 271:G582.</a></li><li><a class="nounderline abstract_t">Pozo D, Delgado M. The many faces of VIP in neuroimmunology: a cytokine rather a neuropeptide? FASEB J 2004; 18:1325.</a></li><li><a class="nounderline abstract_t">Delgado M, Pozo D, Ganea D. The significance of vasoactive intestinal peptide in immunomodulation. Pharmacol Rev 2004; 56:249.</a></li><li><a class="nounderline abstract_t">Ganea D, Hooper KM, Kong W. The neuropeptide vasoactive intestinal peptide: direct effects on immune cells and involvement in inflammatory and autoimmune diseases. Acta Physiol (Oxf) 2015; 213:442.</a></li><li><a class="nounderline abstract_t">Pozo D, Gonzalez-Rey E, Chorny A, et al. Tuning immune tolerance with vasoactive intestinal peptide: a new therapeutic approach for immune disorders. Peptides 2007; 28:1833.</a></li><li><a class="nounderline abstract_t">Deng S, Xi Y, Wang H, et al. Regulatory effect of vasoactive intestinal peptide on the balance of Treg and Th17 in collagen-induced arthritis. Cell Immunol 2010; 265:105.</a></li><li><a class="nounderline abstract_t">Arranz A, Abad C, Juarranz Y, et al. Vasoactive intestinal peptide as a healing mediator in Crohn's disease. Neuroimmunomodulation 2008; 15:46.</a></li><li><a class="nounderline abstract_t">Jönsson M, Norrgård O, Hansson M, Forsgren S. Decrease in binding for the neuropeptide VIP in response to marked inflammation of the mucosa in ulcerative colitis. Ann N Y Acad Sci 2007; 1107:280.</a></li><li><a class="nounderline abstract_t">Neunlist M, Toumi F, Oreschkova T, et al. Human ENS regulates the intestinal epithelial barrier permeability and a tight junction-associated protein ZO-1 via VIPergic pathways. Am J Physiol Gastrointest Liver Physiol 2003; 285:G1028.</a></li><li><a class="nounderline abstract_t">Margolis KG, Gershon MD. Neuropeptides and inflammatory bowel disease. Curr Opin Gastroenterol 2009; 25:503.</a></li><li><a class="nounderline abstract_t">Hamasaki Y, Mojarad M, Said SI. Relaxant action of VIP on cat pulmonary artery: comparison with acetylcholine, isoproterenol, and PGE1. J Appl Physiol Respir Environ Exerc Physiol 1983; 54:1607.</a></li><li><a class="nounderline abstract_t">Hamidi SA, Prabhakar S, Said SI. Enhancement of pulmonary vascular remodelling and inflammatory genes with VIP gene deletion. Eur Respir J 2008; 31:135.</a></li><li><a class="nounderline abstract_t">Dewachter L, Dewachter C, Naeije R. New therapies for pulmonary arterial hypertension: an update on current bench to bedside translation. Expert Opin Investig Drugs 2010; 19:469.</a></li><li><a class="nounderline abstract_t">Colwell CS, Michel S, Itri J, et al. Disrupted circadian rhythms in VIP- and PHI-deficient mice. Am J Physiol Regul Integr Comp Physiol 2003; 285:R939.</a></li><li><a class="nounderline abstract_t">Abad C, Tan YV, Cheung-Lau G, et al. VIP deficient mice exhibit resistance to lipopolysaccharide induced endotoxemia with an intrinsic defect in proinflammatory cellular responses. PLoS One 2012; 7:e36922.</a></li><li><a class="nounderline abstract_t">Cernuda-Morollón E, Martínez-Camblor P, Alvarez R, et al. Increased VIP levels in peripheral blood outside migraine attacks as a potential biomarker of cranial parasympathetic activation in chronic migraine. Cephalalgia 2015; 35:310.</a></li><li><a class="nounderline abstract_t">Riesco N, Cernuda-Morollón E, Martínez-Camblor P, et al. Relationship between serum levels of VIP, but not of CGRP, and cranial autonomic parasympathetic symptoms: A study in chronic migraine patients. Cephalalgia 2017; 37:823.</a></li><li><a class="nounderline abstract_t">Tajti J, Szok D, Majláth Z, et al. Migraine and neuropeptides. Neuropeptides 2015; 52:19.</a></li><li><a class="nounderline abstract_t">Moody TW, Moreno P, Jensen RT. Neuropeptides as lung cancer growth factors. Peptides 2015; 72:106.</a></li><li><a class="nounderline abstract_t">Moody TW, Nuche-Berenguer B, Jensen RT. Vasoactive intestinal peptide/pituitary adenylate cyclase activating polypeptide, and their receptors and cancer. Curr Opin Endocrinol Diabetes Obes 2016; 23:38.</a></li><li><a class="nounderline abstract_t">Sanlioglu AD, Karacay B, Balci MK, et al. Therapeutic potential of VIP vs PACAP in diabetes. J Mol Endocrinol 2012; 49:R157.</a></li><li><a class="nounderline abstract_t">Said SI, Faloona GR. Elevated plasma and tissue levels of vasoactive intestinal polypeptide in the watery-diarrhea syndrome due to pancreatic, bronchogenic and other tumors. N Engl J Med 1975; 293:155.</a></li><li><a class="nounderline abstract_t">Smith SL, Branton SA, Avino AJ, et al. Vasoactive intestinal polypeptide secreting islet cell tumors: a 15-year experience and review of the literature. Surgery 1998; 124:1050.</a></li><li><a class="nounderline abstract_t">Virgolini I, Raderer M, Kurtaran A, et al. Vasoactive intestinal peptide-receptor imaging for the localization of intestinal adenocarcinomas and endocrine tumors. N Engl J Med 1994; 331:1116.</a></li><li><a class="nounderline abstract_t">Pallela VR, Thakur ML, Chakder S, Rattan S. 99mTc-labeled vasoactive intestinal peptide receptor agonist: functional studies. J Nucl Med 1999; 40:352.</a></li><li><a class="nounderline abstract_t">Tang B, Yong X, Xie R, et al. Vasoactive intestinal peptide receptor-based imaging and treatment of tumors (Review). Int J Oncol 2014; 44:1023.</a></li><li><a class="nounderline abstract_t">Schuster DM, Nanni C, Fanti S. PET Tracers Beyond FDG in Prostate Cancer. Semin Nucl Med 2016; 46:507.</a></li><li><a class="nounderline abstract_t">Trabulsi EJ, Tripathi SK, Gomella L, et al. Development of a voided urine assay for detecting prostate cancer non-invasively: a pilot study. BJU Int 2017; 119:885.</a></li><li><a class="nounderline abstract_t">Moody TW, Jensen RT. Pituitary adenylate cyclase-activating polypeptide/vasoactive intestinal peptide [Part 1]: biology, pharmacology, and new insights into their cellular basis of action/signaling which are providing new therapeutic targets. Curr Opin Endocrinol Diabetes Obes 2021; 28:198.</a></li><li><a class="nounderline abstract_t">Sohn W, Lee OY, Lee SP, et al. Mast cell number, substance P and vasoactive intestinal peptide in irritable bowel syndrome with diarrhea. Scand J Gastroenterol 2014; 49:43.</a></li><li><a class="nounderline abstract_t">Palsson OS, Morteau O, Bozymski EM, et al. Elevated vasoactive intestinal peptide concentrations in patients with irritable bowel syndrome. Dig Dis Sci 2004; 49:1236.</a></li><li><a class="nounderline abstract_t">Bednarska O, Walter SA, Casado-Bedmar M, et al. Vasoactive Intestinal Polypeptide and Mast Cells Regulate Increased Passage of Colonic Bacteria in Patients With Irritable Bowel Syndrome. Gastroenterology 2017; 153:948.</a></li><li><a class="nounderline abstract_t">Duffy LC, Zielezny MA, Riepenhoff-Talty M, et al. Vasoactive intestinal peptide as a laboratory supplement to clinical activity index in inflammatory bowel disease. Dig Dis Sci 1989; 34:1528.</a></li><li><a class="nounderline abstract_t">Larsson LT, Sundler F. Is the reduction of VIP the clue to the pathophysiology of Hirschsprung's disease? Z Kinderchir 1990; 45:164.</a></li><li><a class="nounderline abstract_t">Aggestrup S, Uddman R, Sundler F, et al. Lack of vasoactive intestinal polypeptide nerves in esophageal achalasia. Gastroenterology 1983; 84:924.</a></li><li><a class="nounderline abstract_t">Heinz-Erian P, Dey RD, Flux M, Said SI. Deficient vasoactive intestinal peptide innervation in the sweat glands of cystic fibrosis patients. Science 1985; 229:1407.</a></li><li><a class="nounderline abstract_t">Vaidya B, Gupta V. Novel therapeutic approaches for pulmonary arterial hypertension: Unique molecular targets to site-specific drug delivery. J Control Release 2015; 211:118.</a></li><li><a class="nounderline abstract_t">Gonzalez-Rey E, Varela N, Chorny A, Delgado M. Therapeutical approaches of vasoactive intestinal peptide as a pleiotropic immunomodulator. Curr Pharm Des 2007; 13:1113.</a></li></ol></div><div id="topicVersionRevision">Topic 2562 Version 17.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5450698" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Polypeptide with broad biological activity: isolation from small intestine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5415118" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Potent peripheral and splanchnic vasodilator peptide from normal gut.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5415118" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Potent peripheral and splanchnic vasodilator peptide from normal gut.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8903937" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Mutations and diseases of G protein coupled receptors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3025882" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Structure and expression of the gene encoding the vasoactive intestinal peptide precursor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7724664" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Neuropeptides as regulators of airway function: vasoactive intestinal peptide and the tachykinins.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2842874" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Sequential expression in the nervous system of c-myb and VIP genes, located in human chromosomal region 6q24.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2441796" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Developmental expression of the VIP-gene in brain and intestine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6129483" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Are peptide histidine isoleucine and vasoactive intestinal peptide co-synthesised in the same pro-hormone?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2987932" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Coding sequences for vasoactive intestinal peptide and PHM-27 peptide are located on two adjacent exons in the human genome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3023426" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Peptide histidine-methionine immunoreactivity in plasma and tissue from patients with vasoactive intestinal peptide-secreting tumors and watery diarrhea syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6897669" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : PHI stimulates intestinal fluid secretion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2436086" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Projections of peptide-containing neurons in rat small intestine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10634154" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Projections of nitric oxide synthase and vasoactive intestinal polypeptide-reactive submucosal neurons in the human colon.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10657496" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Distribution of calcitonin-gene-related peptide, neuropeptide-Y, vasoactive intestinal polypeptide, cholecystokinin-8, substance P and islet peptides in the pancreas of normal and diabetic rats.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10095862" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Immunohistochemical detection of vasoactive intestinal polypeptide (VIP) and the VIP receptor in the rat inner ear.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10192536" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Regional difference in the distribution of vasoactive intestinal polypeptide-immunoreactive nerve fibres along the uterus and between myometrial muscle layers in the rat.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10067855" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : A cloned frog vasoactive intestinal polypeptide/pituitary adenylate cyclase-activating polypeptide receptor exhibits pharmacological and tissue distribution characteristics of both VPAC1 and VPAC2 receptors in mammals.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9928040" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Autoradiographic visualization of the receptor subclasses for vasoactive intestinal polypeptide (VIP) in rat brain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9647867" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : International Union of Pharmacology. XVIII. Nomenclature of receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8103215" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Transmitter role of vasoactive intestinal peptide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34357396" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Effect of Vasoactive Intestinal Polypeptide on Development of Migraine Headaches: A Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7439634" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Neural release of vasoactive intestinal peptide from the gut.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4359620" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Endocrine pancreatic islet disease with diarrhea. Report of a case due to diffuse hyperplasia of nonbeta islet tissue with a review of 54 additional cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/208414" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Vasoactive intestinal peptide, the major mediator of the WDHA (pancreatic cholera) syndrome: value of measurement in diagnosis and treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10824894" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Pancreatic vasoactive intestinal polypeptide-oma as a cause of secretory diarrhoea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6098877" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Corelease of vasoactive intestinal polypeptide and peptide histidine isoleucine in relation to atropine-resistant vasodilation in cat submandibular salivary gland.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3548423" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : VIP and PHI in the pig pancreas: coexistence, corelease, and cooperative effects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2886054" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Corelease of PHI and VIP by vagal stimulation in the dog.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1964906" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Nitric oxide and vasoactive intestinal polypeptide mediate non-adrenergic, non-cholinergic inhibitory transmission to smooth muscle of the rat gastric fundus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15320758" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Interaction of NO and VIP in gastrointestinal smooth muscle relaxation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15134862" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Neurotransmitters co-existing with VIP or PACAP.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9756514" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Neural mediation of vasoactive intestinal polypeptide inhibitory effect on jejunal alanine absorption.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10419925" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Vasoactive intestinal polypeptide is a potent regulator of bile secretion from rat cholangiocytes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9886989" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Mechanism of inhibition of VIP-induced LES relaxation by heme oxygenase inhibitor zinc protoporphyrin IX.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10710287" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Thyrotropin-releasing hormone interacts with vasoactive intestinal peptide-specific receptor in guinea pig cecal circular smooth muscle cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9108448" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Vasoactive intestinal peptide (VIP) stimulates in vitro growth of VIP-1 receptor-bearing human pancreatic adenocarcinoma-derived cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6107863" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : VIP as a possible neurotransmitter of non-cholinergic non-adrenergic inhibitory neurones.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8447417" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Interplay of VIP and nitric oxide in regulation of the descending relaxation phase of peristalsis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8897876" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Interaction between prostanoids, NO, and VIP in modulation of duodenal alkaline secretion and motility.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15333575" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : The many faces of VIP in neuroimmunology: a cytokine rather a neuropeptide?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15169929" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : The significance of vasoactive intestinal peptide in immunomodulation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25422088" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : The neuropeptide vasoactive intestinal peptide: direct effects on immune cells and involvement in inflammatory and autoimmune diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17521775" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Tuning immune tolerance with vasoactive intestinal peptide: a new therapeutic approach for immune disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20716449" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Regulatory effect of vasoactive intestinal peptide on the balance of Treg and Th17 in collagen-induced arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18667799" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Vasoactive intestinal peptide as a healing mediator in Crohn's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17804556" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Decrease in binding for the neuropeptide VIP in response to marked inflammation of the mucosa in ulcerative colitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12881224" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Human ENS regulates the intestinal epithelial barrier permeability and a tight junction-associated protein ZO-1 via VIPergic pathways.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19816171" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Neuropeptides and inflammatory bowel disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6874483" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Relaxant action of VIP on cat pulmonary artery: comparison with acetylcholine, isoproterenol, and PGE1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18166594" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Enhancement of pulmonary vascular remodelling and inflammatory genes with VIP gene deletion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20367190" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : New therapies for pulmonary arterial hypertension: an update on current bench to bedside translation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12855416" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Disrupted circadian rhythms in VIP- and PHI-deficient mice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22615845" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : VIP deficient mice exhibit resistance to lipopolysaccharide induced endotoxemia with an intrinsic defect in proinflammatory cellular responses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24847167" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Increased VIP levels in peripheral blood outside migraine attacks as a potential biomarker of cranial parasympathetic activation in chronic migraine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27250233" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Relationship between serum levels of VIP, but not of CGRP, and cranial autonomic parasympathetic symptoms: A study in chronic migraine patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26094101" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Migraine and neuropeptides.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25836991" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Neuropeptides as lung cancer growth factors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26702849" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Vasoactive intestinal peptide/pituitary adenylate cyclase activating polypeptide, and their receptors and cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22991228" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Therapeutic potential of VIP vs PACAP in diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/166313" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Elevated plasma and tissue levels of vasoactive intestinal polypeptide in the watery-diarrhea syndrome due to pancreatic, bronchogenic and other tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9854582" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Vasoactive intestinal polypeptide secreting islet cell tumors: a 15-year experience and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7935635" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Vasoactive intestinal peptide-receptor imaging for the localization of intestinal adenocarcinomas and endocrine tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10025846" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : 99mTc-labeled vasoactive intestinal peptide receptor agonist: functional studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24481544" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Vasoactive intestinal peptide receptor-based imaging and treatment of tumors (Review).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27825431" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : PET Tracers Beyond FDG in Prostate Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28075510" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Development of a voided urine assay for detecting prostate cancer non-invasively: a pilot study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33449573" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Pituitary adenylate cyclase-activating polypeptide/vasoactive intestinal peptide [Part 1]: biology, pharmacology, and new insights into their cellular basis of action/signaling which are providing new therapeutic targets.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24256141" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Mast cell number, substance P and vasoactive intestinal peptide in irritable bowel syndrome with diarrhea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15387352" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Elevated vasoactive intestinal peptide concentrations in patients with irritable bowel syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28711627" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Vasoactive Intestinal Polypeptide and Mast Cells Regulate Increased Passage of Colonic Bacteria in Patients With Irritable Bowel Syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2791804" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Vasoactive intestinal peptide as a laboratory supplement to clinical activity index in inflammatory bowel disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2375187" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Is the reduction of VIP the clue to the pathophysiology of Hirschsprung's disease?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6832568" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Lack of vasoactive intestinal polypeptide nerves in esophageal achalasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4035357" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Deficient vasoactive intestinal peptide innervation in the sweat glands of cystic fibrosis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26036906" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Novel therapeutic approaches for pulmonary arterial hypertension: Unique molecular targets to site-specific drug delivery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17430175" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Therapeutical approaches of vasoactive intestinal peptide as a pleiotropic immunomodulator.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
